Boston Scientific Shares Drop 3.4% Following Downgrade
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 29 2026
0mins
Should l Buy BSX?
Source: Yahoo Finance
- Stock Price Decline: Boston Scientific (BSX) shares fell 3.4% during Wednesday afternoon trading, indicating market concerns about the company's future performance, which could impact investor confidence and lead to short-term capital outflows.
- Rating Downgrade Impact: The decline in stock price is linked to a downgrade by Daiwa Securities, suggesting that the market's sensitivity to analyst opinions may have exacerbated the stock's volatility, highlighting investors' heavy reliance on external ratings.
- Market Reaction: The drop in stock price could affect Boston Scientific's market capitalization, which in turn may impact its financing capabilities and future investment plans, especially in the context of intense competition in the medical device industry.
- Investor Sentiment: Changes in analyst ratings often trigger fluctuations in market sentiment, and Boston Scientific needs to take measures to restore investor confidence to avoid further declines in stock price.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BSX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BSX
Wall Street analysts forecast BSX stock price to rise
22 Analyst Rating
22 Buy
0 Hold
0 Sell
Strong Buy
Current: 56.570
Low
94.00
Averages
108.14
High
132.00
Current: 56.570
Low
94.00
Averages
108.14
High
132.00
About BSX
Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Market Analysis: ASML and Steel Dynamics Performance
- ASML Stock Performance: ASML's stock has been on a continuous rise since its impressive quarterly results, with a $75 increase today, reflecting strong market confidence in its technological leadership despite concerns about a potential pullback.
- Steel Dynamics Recommendation: Steel Dynamics is viewed as an excellent company, with analysts strongly recommending buying its stock, indicating confidence in its future profitability and reflecting the stable demand and growth potential in the steel industry.
- Bloom Energy Investment Opportunity: Bloom Energy is highlighted as a non-combustible power investment choice, with analysts noting a surge in demand from data centers, underscoring its significance and growth potential in the renewable energy market.
- Amphenol Stock Pullback: Amphenol's stock has slightly decreased, which analysts see as a good buying opportunity, demonstrating market confidence in its long-term growth prospects, particularly amid ongoing demand in the connectors and sensors market.
See More
Domino's Pizza Stock Performance Analysis
- Stock Performance Assessment: Domino's Pizza has shown poor stock performance this year, with analysts indicating that despite its potential, the current market environment is unfavorable, suggesting a need for a quarter's observation period before making further investment decisions.
- Gold Market Outlook: Analysts at Agnico Eagle Mines express a bearish outlook on the gold market, citing renowned analyst Larry Williams' perspective that gold prices are likely to decline further, which could impact the investment appeal of related mining companies.
- Investor Sentiment Shift: Jim Cramer expresses a pessimistic view on gold during his show, highlighting that changes in market sentiment may lead investors to reassess their asset allocations, particularly in the precious metals sector.
- Market Strategy Adjustment: As the outlook for both Domino's Pizza and gold becomes more cautious, investors may need to reconsider their investment strategies to navigate potential market volatility and uncertainty.
See More
Boston Scientific Class Action Lawsuit Reminder
- Lawsuit Background: Boston Scientific Corporation (NYSE:BSX) is facing a class action lawsuit for making misleading statements during the period from July 23, 2025, to February 3, 2026, with a lead plaintiff motion deadline of May 4, 2026.
- Growth Rate Concerns: The lawsuit alleges that the growth rate of Boston Scientific's U.S. Electrophysiology (EP) segment was unsustainable and approaching a tipping point earlier than anticipated, severely impacting investor confidence in the company's future.
- Competitive Pressure: The company is experiencing new entrants in the market that are eroding its market share in U.S. Electrophysiology, thereby limiting its growth potential and increasing the risk of investor losses.
- Misleading Statements: Executives at Boston Scientific repeatedly expressed confidence in the growth trajectory of its EP division, but these positive statements are alleged to lack a reasonable basis, misleading investors about the company's business outlook.
See More
Boston Scientific to Participate in Strategic Decisions Conference
- Conference Participation: Boston Scientific will participate in Bernstein's 42nd Annual Strategic Decisions Conference on May 27, 2026, with CEO Mike Mahoney and CMO Janar Sathananthan engaging in a 50-minute Q&A session, which is expected to enhance investor understanding of the company's strategy.
- Earnings Call: The company will host a conference call on July 29, 2026, at 8:00 AM ET to discuss financial results and business highlights for the second quarter ended June 30, thereby increasing transparency and attracting investor interest.
- Financial Results Announcement: Boston Scientific will issue a news release announcing its second-quarter 2026 financial results prior to the earnings call, ensuring that investors receive timely key information that could influence market expectations regarding the company's future performance.
- Webcast Availability: Live webcasts and replays of each event will be accessible on the company's investor website, enhancing information accessibility and ensuring that investors can stay updated on the latest company developments.
See More
Market Recovers but Growth Stocks Struggle
- ServiceNow Performance Review: Despite achieving a 20% revenue growth in 2022 and a 19% growth in Q1 2023, ServiceNow's stock has plummeted over 50% from its July peak, reflecting an overreaction from the market towards AI stocks, resulting in a three-year low market cap.
- Roblox Growth Slowdown: The recently implemented age verification measures have led Roblox to revise its 2023 revenue growth forecast down from 23%-29% to 20%-25%, even though last quarter's revenue reached $1.4 billion, a 39% increase, indicating short-term market pressures.
- Boston Scientific Outlook Adjustment: Boston Scientific's Watchman implant showed promising results in trials, but the unclear long-term benefits have caused a reduction in its 2026 revenue growth forecast from 10%-11% to 6.5%-8%, although analysts remain optimistic, viewing the current stock price as a buying opportunity.
- Market Sentiment Analysis: Following a strong rebound in April, the overall market has seen certain growth stocks suffer due to fluctuating market sentiment, prompting investors to carefully assess the long-term value versus short-term volatility of these stocks.
See More
Boston Scientific Class Action Reminder for Investors
- Class Action Notice: Rosen Law Firm reminds investors who purchased Boston Scientific stock between July 23, 2025, and February 3, 2026, that they must apply to be lead plaintiff by May 4, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that Boston Scientific made false and misleading statements during the class period, leading to investor losses when the company missed net income expectations for the first quarter, revealing management's concealment of unsustainable growth in its electrophysiology segment.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked first in 2017 for the number of securities class action settlements, demonstrating its expertise and success in this field.
- Investor Selection Advice: Investors are advised to be cautious when selecting legal counsel, avoiding inexperienced intermediaries, and ensuring that their chosen law firm has the capability to handle securities class actions to maximize potential recovery opportunities.
See More
Market Analysis: ASML and Steel Dynamics Performance
- ASML Stock Performance: ASML's stock has been on a continuous rise since its impressive quarterly results, with a $75 increase today, reflecting strong market confidence in its technological leadership despite concerns about a potential pullback.
- Steel Dynamics Recommendation: Steel Dynamics is viewed as an excellent company, with analysts strongly recommending buying its stock, indicating confidence in its future profitability and reflecting the stable demand and growth potential in the steel industry.
- Bloom Energy Investment Opportunity: Bloom Energy is highlighted as a non-combustible power investment choice, with analysts noting a surge in demand from data centers, underscoring its significance and growth potential in the renewable energy market.
- Amphenol Stock Pullback: Amphenol's stock has slightly decreased, which analysts see as a good buying opportunity, demonstrating market confidence in its long-term growth prospects, particularly amid ongoing demand in the connectors and sensors market.
See More
Domino's Pizza Stock Performance Analysis
- Stock Performance Assessment: Domino's Pizza has shown poor stock performance this year, with analysts indicating that despite its potential, the current market environment is unfavorable, suggesting a need for a quarter's observation period before making further investment decisions.
- Gold Market Outlook: Analysts at Agnico Eagle Mines express a bearish outlook on the gold market, citing renowned analyst Larry Williams' perspective that gold prices are likely to decline further, which could impact the investment appeal of related mining companies.
- Investor Sentiment Shift: Jim Cramer expresses a pessimistic view on gold during his show, highlighting that changes in market sentiment may lead investors to reassess their asset allocations, particularly in the precious metals sector.
- Market Strategy Adjustment: As the outlook for both Domino's Pizza and gold becomes more cautious, investors may need to reconsider their investment strategies to navigate potential market volatility and uncertainty.
See More
Boston Scientific Class Action Lawsuit Reminder
- Lawsuit Background: Boston Scientific Corporation (NYSE:BSX) is facing a class action lawsuit for making misleading statements during the period from July 23, 2025, to February 3, 2026, with a lead plaintiff motion deadline of May 4, 2026.
- Growth Rate Concerns: The lawsuit alleges that the growth rate of Boston Scientific's U.S. Electrophysiology (EP) segment was unsustainable and approaching a tipping point earlier than anticipated, severely impacting investor confidence in the company's future.
- Competitive Pressure: The company is experiencing new entrants in the market that are eroding its market share in U.S. Electrophysiology, thereby limiting its growth potential and increasing the risk of investor losses.
- Misleading Statements: Executives at Boston Scientific repeatedly expressed confidence in the growth trajectory of its EP division, but these positive statements are alleged to lack a reasonable basis, misleading investors about the company's business outlook.
See More
Boston Scientific to Participate in Strategic Decisions Conference
- Conference Participation: Boston Scientific will participate in Bernstein's 42nd Annual Strategic Decisions Conference on May 27, 2026, with CEO Mike Mahoney and CMO Janar Sathananthan engaging in a 50-minute Q&A session, which is expected to enhance investor understanding of the company's strategy.
- Earnings Call: The company will host a conference call on July 29, 2026, at 8:00 AM ET to discuss financial results and business highlights for the second quarter ended June 30, thereby increasing transparency and attracting investor interest.
- Financial Results Announcement: Boston Scientific will issue a news release announcing its second-quarter 2026 financial results prior to the earnings call, ensuring that investors receive timely key information that could influence market expectations regarding the company's future performance.
- Webcast Availability: Live webcasts and replays of each event will be accessible on the company's investor website, enhancing information accessibility and ensuring that investors can stay updated on the latest company developments.
See More
Market Recovers but Growth Stocks Struggle
- ServiceNow Performance Review: Despite achieving a 20% revenue growth in 2022 and a 19% growth in Q1 2023, ServiceNow's stock has plummeted over 50% from its July peak, reflecting an overreaction from the market towards AI stocks, resulting in a three-year low market cap.
- Roblox Growth Slowdown: The recently implemented age verification measures have led Roblox to revise its 2023 revenue growth forecast down from 23%-29% to 20%-25%, even though last quarter's revenue reached $1.4 billion, a 39% increase, indicating short-term market pressures.
- Boston Scientific Outlook Adjustment: Boston Scientific's Watchman implant showed promising results in trials, but the unclear long-term benefits have caused a reduction in its 2026 revenue growth forecast from 10%-11% to 6.5%-8%, although analysts remain optimistic, viewing the current stock price as a buying opportunity.
- Market Sentiment Analysis: Following a strong rebound in April, the overall market has seen certain growth stocks suffer due to fluctuating market sentiment, prompting investors to carefully assess the long-term value versus short-term volatility of these stocks.
See More
Boston Scientific Class Action Reminder for Investors
- Class Action Notice: Rosen Law Firm reminds investors who purchased Boston Scientific stock between July 23, 2025, and February 3, 2026, that they must apply to be lead plaintiff by May 4, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that Boston Scientific made false and misleading statements during the class period, leading to investor losses when the company missed net income expectations for the first quarter, revealing management's concealment of unsustainable growth in its electrophysiology segment.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked first in 2017 for the number of securities class action settlements, demonstrating its expertise and success in this field.
- Investor Selection Advice: Investors are advised to be cautious when selecting legal counsel, avoiding inexperienced intermediaries, and ensuring that their chosen law firm has the capability to handle securities class actions to maximize potential recovery opportunities.
See More
